Home/Pipeline/Cancer Vaccines (undisclosed)

Cancer Vaccines (undisclosed)

Cancer

Pre-clinicalActive

Key Facts

Indication
Cancer
Phase
Pre-clinical
Status
Active
Company

About Takis

Takis is a private, Rome-based biotech firm operating as both a service provider (CRO) and a therapeutic developer. Its core focus is on discovering and developing novel immunotherapies, primarily therapeutic antibodies and DNA/mRNA vaccines for oncology and infectious diseases. The company possesses over a decade of experience in drug discovery, validated preclinical models, and advanced manufacturing capabilities, positioning it as a specialized partner in the European biotech ecosystem. While it advances its own pipeline candidates towards early-phase trials, its service arm generates revenue through collaborations with pharmaceutical and research clients.

View full company profile

Other Cancer Drugs

DrugCompanyPhase
Not Specified (Oncology Focus)Narwhal BioPre-clinical
EDM Platform for Genetic MedicineCoastar TherapeuticsPre-clinical
CO-1Caedo OncologyPre-clinical
Anti-CD99 monoclonal antibodyCaedo OncologyDiscovery/Pre-clinical
Anti-HLA class I monoclonal antibodyCaedo OncologyDiscovery/Pre-clinical
Triapine®NanopharmaceuticsClinical
Ammonium TetrathiomolybdateNanopharmaceuticsClinical
Aza-TdCNanopharmaceuticsClinical
Undisclosed Oncology Program(s)Cell BioEnginesPhase 1
No-alpha IL-2 MuteinSarcoMed USAPre-clinical
PMIS TherapeuticNaturemiRIPreclinical/Clinical (unspecified)
AUM302 (formerly IBL-302)Inflection BiosciencesPre-clinical (partnered)